ZK-01-2021

Zura Bio is a clinical-stage biotechnology company focused on developing novel dual-pathway antibodies for the treatment of serious immune-mediated and inflammatory diseases. The company's lead asset, ZB-168 (formerly ZK-01-2021), is a monoclonal antibody targeting the IL-7 receptor alpha chain, which plays a critical role in both IL-7 and TSLP signaling pathways. By inhibiting these pathways, Zura Bio aims to address the underlying drivers of conditions such as alopecia areata and atopic dermatitis. The company is also advancing ZB-106, a dual antagonist of IL-17A and IL-17F, further expanding its portfolio in the immunology space.